123 related articles for article (PubMed ID: 9339197)
1. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Launois RJ; Reboul-Marty JM; Bonneterre J
Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
[TBL] [Abstract][Full Text] [Related]
2. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Launois R; Reboul-Marty J; Henry B; Bonneterre J
Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
4. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
6. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
7. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
Verma S; Ilersich AL
Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Benedict A; Cameron DA; Corson H; Jones SE
Pharmacoeconomics; 2009; 27(10):847-59. PubMed ID: 19803539
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Brown RE; Hutton J
Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of taxane therapy.
Yee GC
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S11-5. PubMed ID: 9435927
[TBL] [Abstract][Full Text] [Related]
12. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
14. Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
Aapro MS
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):46-9. PubMed ID: 9364543
[TBL] [Abstract][Full Text] [Related]
15. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
17. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of docetaxel versus weekly paclitaxel in adjuvant treatment of regional breast cancer in New Zealand.
Webber-Foster R; Kvizhinadze G; Rivalland G; Blakely T
Pharmacoeconomics; 2014 Jul; 32(7):707-24. PubMed ID: 24859241
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of nanoparticle albumin-bound paclitaxel versus paclitaxel in monotherapy in pretreated metastatic breast cancer in Spain.
Alba E; Ciruelos E; López R; López-Vega JM; Lluch A; Martín M; Muñoz M; Sánchez-Rovira P; Seguí MÁ; Liria MR; Pérez-Alcántara F
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):381-91. PubMed ID: 23534988
[TBL] [Abstract][Full Text] [Related]
20. A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.
Li N; van Agthoven M; Willemse P; Uyl-de Groot C
Anticancer Drugs; 2001 Jul; 12(6):533-40. PubMed ID: 11460000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
